1. Health Canada. Regulatory decision summary. Pr Sotrovimab: Health Canada, 2021, https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00836; (accessed March 5, 2023).
2. Monoclonal antibodies for the treatment of Covid-19-every day you fight like you're running out of time;McCreary;JAMA Netw Open,2023
3. Health Canada. Health professional risk communication: Sotrovimab for injection - Risk of treatment failure due to circulation of SARS-C0V-2 Omicron BA.2 subvariant, https://recalls-rappels.canada.ca/en/alert-recall/sotrovimab-injection-risk-treatment-failure-due-circulation-sars-cov-2-omicron-ba2; 2022 [accessed 04 July 2023].
4. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study;Evans;J Infect,2023
5. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe Covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform;Zheng;BMJ,2022